https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=33115874&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09 331158742021031620210623
1098-55149522020Dec22Journal of virologyJ VirolRelationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV.e01808-2010.1128/JVI.01808-20RenYanqinYDivision of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.KoromMariaMDept. of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.WardAdam RARDivision of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.Dept. of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.TruongRonaldRDept. of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.ChanDoraDDept. of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.HuangSzu-HanSHDivision of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.Dept. of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.KovacsColin MCMMaple Leaf Medical Clinic, Toronto, Ontario, Canada.BenkoErikaEMaple Leaf Medical Clinic, Toronto, Ontario, Canada.SafritJeffrey TJTNantBioScience Inc., NantKwest LLC, Culver City, California, USA.LeeJohnJNantBioScience Inc., NantKwest LLC, Culver City, California, USA.GarbánHermesHNantWorks, LLC, Culver City, California, USA.LynchRebeccaRDept. of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington, DC, USA.JonesR BradRB0000-0003-4470-1231Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA rbjones@med.cornell.edu.engR21 AI152828AINIAID NIH HHSUnited StatesR01 AI131798AINIAID NIH HHSUnited StatesUM1 AI126617AINIAID NIH HHSUnited StatesR01 AI147845AINIAID NIH HHSUnited StatesR01 AI052764AINIAID NIH HHSUnited StatesLetter20201222
United StatesJ Virol01137240022-538X0Broadly Neutralizing Antibodies0HIV AntibodiesIMAntibody-Dependent Cell CytotoxicityimmunologyBinding Sites, AntibodyBroadly Neutralizing AntibodiesimmunologyCell LineHIVimmunologyHIV AntibodiesimmunologyHumansNeutralization TestsHIVHIV cureantibody neutralizationantibody-dependent cellular cytotoxicitybroadly neutralizing antibodies2020103060202131760202010295412021622epublish33115874PMC794444210.1128/JVI.01808-20JVI.01808-20Danesh A, Ren Y, Brad Jones R. 2020. Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV. Curr Opin HIV AIDS 15:316–323. doi:10.1097/COH.0000000000000644.10.1097/COH.0000000000000644PMC774834132732552Richard J, Prévost J, Baxter AE, von Bredow B, Ding S, Medjahed H, Delgado GG, Brassard N, Stürzel CM, Kirchhoff F, Hahn BH, Parsons MS, Kaufmann DE, Evans DT, Finzi A. 2018. Uninfected bystander cells impact the measurement of HIV-specific antibody-dependent cellular cytotoxicity responses. mBio 9:e00358-18. doi:10.1128/mBio.00358-18.10.1128/mBio.00358-18PMC587491329559570Parsons MS, Lee WS, Kristensen AB, Amarasena T, Khoury G, Wheatley AK, Reynaldi A, Wines BD, Hogarth PM, Davenport MP, Kent SJ. 2019. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J Clin Invest 129:182–191. doi:10.1172/JCI122466.10.1172/JCI122466PMC630796330475230Asokan M, Dias J, Liu C, Maximova A, Ernste K, Pegu A, McKee K, Shi W, Chen X, Almasri C, Promsote W, Ambrozak DR, Gama L, Hu J, Douek DC, Todd JP, Lifson JD, Fourati S, Sekaly RP, Crowley AR, Ackerman ME, Ko SH, Kilam D, Boritz EA, Liao LE, Best K, Perelson AS, Mascola JR, Koup RA. 2020. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc Natl Acad Sci U S A 117:18754–18763. doi:10.1073/pnas.2008236117.10.1073/pnas.2008236117PMC741404632690707Ren Y, Korom M, Truong R, Chan D, Huang SH, Kovacs CC, Benko E, Safrit JT, Lee J, Garban H, Apps R, Goldstein H, Lynch RM, Jones RB. 2018. Susceptibility to neutralization by broadly neutralizing antibodies generally correlates with infected cell binding for a panel of clade B HIV reactivated from latent reservoirs. J Virol 92:e00895-18. doi:10.1128/JVI.00895-18.10.1128/JVI.00895-18PMC623247930209173von Bredow B, Arias JF, Heyer LN, Gardner MR, Farzan M, Rakasz EG, Evans DT. 2015. Envelope glycoprotein internalization protects human and simian immunodeficiency virus-infected cells from antibody-dependent cell-mediated cytotoxicity. J Virol 89:10648–10655. doi:10.1128/JVI.01911-15.10.1128/JVI.01911-15PMC458015526269175Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, Donahue DA, Lorin V, Casartelli N, Noel N, Lambotte O, Mouquet H, Schwartz O. 2016. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun 7:10844. doi:10.1038/ncomms10844.10.1038/ncomms10844PMC478206426936020Bruel T, Guivel-Benhassine F, Lorin V, Lortat-Jacob H, Baleux F, Bourdic K, Noel N, Lambotte O, Mouquet H, Schwartz O. 2017. Lack of ADCC breadth of human nonneutralizing anti-HIV-1 antibodies. J Virol 91:e02440-16. doi:10.1128/JVI.02440-16.10.1128/JVI.02440-16PMC537567128122982Taylor BM. 2020. A multi-way correlation coefficient. arXiv:2003.02561.